RecruitingPhase 1NCT05904093

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Studying Sickle cell anemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator
Swee Lay Thein, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
Intervention
Fostamatinib(drug)
Enrollment
25 enrolled
Eligibility
18-65 years · All sexes
Timeline
2024 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05904093 on ClinicalTrials.gov

Other trials for Sickle cell anemia

Additional recruiting or active studies for the same condition.

See all trials for Sickle cell anemia →

← Back to all trials